Abstracts
Breast cancer, metastatic
239PD - A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04

https://doi.org/10.1093/annonc/mdx365.002Get rights and content
Under an Elsevier user license
open archive

Cited by (0)